Merck Entered into a Clinical Trial Collaboration with GenFleet Therapeutics to Initiate P-Ib/II Trial of GFH925 + Erbitux (cetuximab) for Non-small cell lung cancer
- The companies collaborated to initiate the P-Ib/II trial evaluating GFH925 + Erbitux (IgG1 mAb targeting EGFR) for patients with NSCLC harboring KRAS G12C mutation
- The preliminary results of GFH925 monotx. from the P-I clinical study showed a favorable safety/tolerability along with a promising antitumor activity profile, presented at ASCO 2022
- GenFleet will be responsible to conduct an open-label study of the combination therapy for the same indication while Merck will be responsible to provide clinical drug supplies of cetuximab in the EU. Additonally, Erbitux targets cytotoxic immune effector cells towards EGFR-expressing tumor cells, in vitro evidence
Ref: PRNewswire | Image: Merck
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.